Screener
PTC Therapeutics PTCT Total Current Liabilities
Total Current Liabilities at other companies
Other financials
Where this comes from
Reported directly by PTC Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.
The source filing: PTC Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:32 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001070081-26-000012
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Operating lease liabilities- current | 12,078 | 12,484 |
| Finance lease liabilities- current | 6,000 | 3,000 |
| Liability for sale of future royalties- current | 305,041 | 283,000 |
| Total current liabilities | 923,604 | 968,427 |
| Operating lease liabilities- noncurrent | 90,072 | 93,583 |
| Finance lease liabilities- noncurrent | — | 3,000 |
| Liability for sale of future royalties- noncurrent | 2,022,189 | 2,025,366 |
| Other long-term liabilities | 13,704 | 13,704 |
Item 1. Financial Statements (unaudited)
FAQ
- What is PTC Therapeutics's total current liabilities?
- PTC Therapeutics (PTCT) reported total current liabilities of $923.6M in Q1 2026.
- How has PTC Therapeutics's total current liabilities changed year-over-year?
- PTC Therapeutics's total current liabilities increased by 55.1% year-over-year, from $595.39M to $923.6M.
- What is the long-term trend for PTC Therapeutics's total current liabilities?
- Over 5 years (2020 to 2025), PTC Therapeutics's total current liabilities has grown at a 28.4% compound annual growth rate (CAGR), from $277.33M to $968.43M.
- What does total current liabilities mean?
- The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.
Ask your AI about PTC Therapeutics's total current liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude